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Human immunodeficiency virus type 1 (HIV-1) non-B subtype infections occurred in
Belgium since the 1980s, mainly amongst migrants and heterosexuals, whereas subtype
B predominated in men-having-sex-with-men (MSM). In the last decade, the diagnosis
of F1 sub-subtype in particular has increased substantially, which prompted us to
perform a detailed reconstruction of its epidemiological history. To this purpose, the
Belgian AIDS Reference Laboratories collected HIV-1 pol sequences from all sub-
subtype F1-infected patients for whom genotypic drug resistance testing was requested
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as part of routine clinical follow-up. This data was complemented with HIV-1 pol
sequences from countries with a high burden of F1 infections or a potential role
in the global origin of sub-subtype F1. The molecular epidemiology of the Belgian
subtype F1 epidemic was investigated using Bayesian phylogenetic inference and
transmission dynamics were characterized based on birth-death models. F1 sequences
were retained from 297 patients diagnosed and linked to care in Belgium between 1988
and 2015. Phylogenetic inference indicated that among the 297 Belgian F1 sequences,
191 belonged to a monophyletic group that mainly contained sequences from people
likely infected in Belgium (OR 26.67, 95% CI 9.59–74.15), diagnosed in Flanders (OR
7.28, 95% CI 4.23–12.53), diagnosed at a recent stage of infection (OR 7.19, 95%
CI 2.88-17.95) or declared to be MSM (OR 34.8, 95% CI 16.0–75.6). Together with a
Spanish clade, this Belgian clade was embedded in the genetic diversity of Brazilian
subtype F1 strains and most probably emerged after one or only a few migration events
from Brazil to the European continent before 2002. The origin of the Belgian outbreak
was dated back to 2002 (95% higher posterior density 2000–2004) and birth-death
models suggested that its extensive growth had been controlled (Re < 1) by 2012,
coinciding with a time period where delay in antiretroviral treatment initiation substantially
declined. In conclusion, phylogenetic reconstruction of the Belgian HIV-1 sub-subtype
F1 epidemic illustrates the introduction and substantial dissemination of viral strains in a
geographically restricted risk group that was most likely controlled by effective treatment
as prevention.
Keywords: HIV-1, sub-subtype F1, Belgium, phylodynamics, men-having-sex-with-men, treatment as prevention
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) originated after
at least four separate cross-species transmission events from non-
human primates to humans in central Africa, which resulted in
four groups (M, N, O, and P) that emerged in the early twentieth
century (Peeters et al., 2014). Since then, HIV-1 group M lineages
have diversified and the current genetic diversity existing within
the pandemic group M is the result of subsequent evolution
and spread within the human population. Using phylogenetic
analysis, HIV-1 group M can be classified into nine major
subtypes (A–D, F–H, J, and K) and a few sub-subtypes (like
F1 and F2) which reflects a combination of several founder
effects and incomplete sampling of the original source population
in central Africa (Rambaut et al., 2004). On the other hand,
the various circulating recombinant forms (CRFs) originated
from co-circulation of subtypes that previously evolved in
compartmentalized epidemics.
The HIV-1 subtype B lineage that is responsible for the
majority of HIV-1 infections in Europe, was first exported from
central Africa to the Caribbean region around 1967 from where it
was subsequently introduced in the United States and spread over
to other American and European countries, mainly via networks
of men-having-sex-with-men (MSM) and people who injects
drugs (PWID) (Abecasis et al., 2013; Junqueira and Almeida,
2016; Magiorkinis et al., 2016; Worobey et al., 2016). HIV-1
subtype B was the predominant subtype among Belgians who
were diagnosed with HIV-1 between 1985 and 1994 in Antwerp
(Belgium), although the presence of other pure subtypes such as
A, C, D, F, G, and H already revealed an early introduction of
HIV-1 non-B subtypes to the local population (Fransen et al.,
1996). Nevertheless, Belgian MSM remained almost exclusively
infected with subtype B strains. These findings were confirmed
in an independent study where heterosexual contact, African
origin and more recent diagnosis were predictors for non-B
infection in HIV-1 patients diagnosed between 1983 and 2001
in two other Belgian cities (Brussels and Leuven) (Snoeck et al.,
2004). Subsequent local and national surveillance studies that
included HIV-1 diagnoses between 1998 and 2012 confirmed the
association between subtype B infections, MSM and Caucasian
origin. In contrast, HIV-1 non-B infections in Belgium, of which
HIV-1 subtype A, C, and CRF02_AG infections were the most
prevalent, were associated to migrants from sub-Saharan Africa
and individuals showing heterosexual risk behavior (Vercauteren
et al., 2008; Chalmet et al., 2010; Pineda-Peña et al., 2014).
In the last decade, sub-subtype F1 diagnoses have markedly
increased among newly diagnosed HIV-1 patients linked to care
in Belgium. In the light of two Spanish studies that reported
lower therapy response rates in HIV-1 sub-subtype F1 infections
(Pernas et al., 2014; Cid-Silva et al., 2018), we aimed to investigate
the evolutionary history and distinctive socio-demographic and
epidemiological features of the HIV-1 sub-subtype F1 epidemic
in Belgium. The spatiotemporal origin of the ancestor of the
Belgian F1 epidemic and evolutionary links among locations
were determined, risk factors were identified, and transmission
dynamics were quantified.
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MATERIALS AND METHODS
Viral Sequences and Associated
Information
Human immunodeficiency virus type 1 sub-subtype F1 pol
sequences spanning the gene fragments that encode protease
(PR) and the 5′-end of reverse transcriptase (RT) were
collected from all patients for whom drug resistance testing
was requested as part of routine clinical follow-up at six
AIDS reference laboratories (ARL) in Antwerp, Brussels, Ghent,
and Leuven (up until March 2015). These ARL perform
approximately 90% of the HIV-1 drug resistance testing in
Belgium. HIV-1 sub-subtype F1 pol sequences were requested
from partners in other European and African countries where
circulation of F1 infections has been reported (Palma et al.,
2007; Paraschiv et al., 2009; Frentz et al., 2010; Lai et al.,
2012; Ivanov et al., 2013; Sayan et al., 2013; Alexiev et al.,
2015). Furthermore, all available HIV-1 sub-subtype F1 pol
sequences were extracted from the Los Alamos HIV Sequence
Database (LANL)1 (Triques et al., 1999; Montano et al., 2005;
Aulicino et al., 2007). Most viral genetic sequences were
annotated with sampling time and location, which were used
as calibration and discrete traits, respectively, in an analysis of
spatiotemporal dispersion patterns (Supplementary Table S1).
Patient socio-demographics and detailed sample information
were collected from mandatory reporting and medical records
at the participating ARL in Belgium (gender, year of birth,
HIV-1 diagnosis date, infection stage at diagnosis, country of
birth, probable country of infection, sexual risk factor for HIV-
1 acquisition, viral load, CD4 and CD8 count associated to
the HIV-1 pol sequence, and therapy initiation date). Infection
stage at diagnosis was defined based upon laboratory data:
HIV-1 confirmation results with a positive p24 test combined
with a negative or undetermined blot or INNO-LIA HIV I/II
(Fujirebio Europe, Ghent, Belgium) were classified as acute
infections while results with a positive blot lacking a p31
band as recent infections (Verhofstede et al., 2017). In all
other instances, at least when records were available, infections
were classified as chronic. The study was approved by the
Ethical Committee Research UZ/KU Leuven (reference S58359).
This study did not require written informed consent by study
participants as it only used data collected within routine clinical
practice, but patients who opted out of research studies were
not included. The entire dataset for this manuscript is not
publicly available because it represents a dense sample of our
epidemic and inappropriate use could endanger the privacy
of the patients. A proportional down-sampling of the dataset
(30%) is accessible via GenBank (accession numbers, MK458435-
MK458523). Requests to access the entire dataset combined
with well-defined project proposals can be mailed to the
corresponding author who will submit it to the local ethical
committee for ethical and legal clearance when not in conflict
with already on-going research.
1http://www.hiv.lanl.gov
Quality Control and Compilation of
Sequences
The quality of HIV-1 sequences that were generated by the
Belgian ARL was assured by quality management systems
that are conform to the ISO 15189 standard. In addition,
the quality of all collected HIV-1 sequences was subsequently
verified using the Quality Control tool hosted on the HIV
sequence database LANL. Only sequences with no evidence
of hyper-mutations and a maximum of 7 stop codons and/or
frameshifts were retained for further analyses. Only pure sub-
subtype F1 strains were retained in the study. Therefore, HIV-1
subtype classification was confirmed using the online automated
subtyping tools COMET v1.0 (Struck et al., 2014) and Rega v3
(Pineda-Peña et al., 2013). In case of a non-F1 classification
by COMET v1.0 or Rega v3 (7% discordant classifications),
sequences were subsequently subjected to jpHMM (Schultz et al.,
2009; version March 2015). If scored as F1 or F2 sub-subtype
by jpHMM, recombination was ruled out using Simplot (Lole
et al., 1999). Four HIV-1 subtype B reference sequences were
added to the dataset, serving as an outgroup for subsequent
phylogenetic analyses (GenBank accession numbers K03455,
AY423387, AY173951, and AY331295). Nucleotide sequences
were aligned using Muscle v3.7 (Edgar, 2004) and manually
edited in MEGA 5 (Tamura et al., 2011). Nucleotide positions
encoding for 43 surveillance drug resistance mutations (Bennett
et al., 2009) were removed from the alignment to avoid the
effect of drug-induced convergent evolution. Duplicate sequences
were identified using the ElimDupes tool (LANL) and were
removed when originating from the same sample. For patients
with multiple sequences, only the first sequence was retained. The
final alignment contained 1866 HIV-1 sub-subtype F1 sequences
trimmed to the common length of 798 nucleotide positions,
spanning sites 2253 to 2549 and 2661 to 3290 (as compared to the
HIV-1 subtype B reference sequence HXB2, accession number
K03455) (Supplementary Table S1).
Phylogenetic and Phylogeographic
Analyses
The spatiotemporal origin of the Belgian HIV-1 sub-subtype F1
epidemic was investigated using a Bayesian approach. Prior to
this analysis, we examined the accumulation of divergence over
the sampling time span using Tempest v1.5 (Rambaut et al., 2016)
to assure that sampling dates could be used as calibration. Markov
chain Monte Carlo analyses were performed using BEAST v1.8.4
in conjunction with BEAGLE to improve the computational
performance (Ayres et al., 2012; Suchard et al., 2018). We
specified a GTR nucleotide substitution model with discrete
gamma distributed rate variation among sites. Among-lineage
variation in evolutionary rates was modeled using a lognormal
relaxed molecular clock and a flexible non-parametric Bayesian
Skygrid was specified as a coalescent prior. The analyses were
run in triplicate for 100 million states and trees were sampled
every 10,000th state. Convergence and mixing properties of the
Markov chain Monte Carlo chains were assessed with Tracer v1.6
(Rambaut et al., 2018). Results of several chains were combined
after removal of the burn-in, and a MCC tree was summarized
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using TreeAnnotator within the BEAST package. The timed
migration process was reconstructed using a model that allows
for non-reversible migration rates. Trees were visualized with
FigTree v1.4.3 and iTOL v4.2.3 (Letunic and Bork, 2016).
Phylodynamic Analysis of the Infection
Cluster Including Belgian Sequences
Phylodynamic analyses were performed on an infection cluster
that mainly contained sequences from our Belgian cohort.
A birth-death model was applied to the Belgian sequences
included in this infection cluster (191 sequences) in order to
quantify transmission dynamics through time. The analyses were
performed in BEAST v2 (Bouckaert et al., 2014) using the
BDSKY add-on (Stadler et al., 2013). The molecular evolution
and clock model were chosen as in the phylogeographic analysis.
For the birth-death-skyline parameters, we used a LogNorm(0,1)
prior for the effective reproductive number, a LogNorm(0,1)
prior for the becoming-non-infectious rate in units per year
(i.e., the inverse of the time duration of being infectious in
unit of years), and a Unif(0,infinity) prior for the origin of the
epidemic. The dimension of the effective reproductive number
and the becoming-non-infectious rate was set to 10, meaning
the parameters were estimated for 10 equally spaced intervals
between the origin and the most recent sample. The sampling
proportion was fixed to 0.65 (and 0.8 in a second analysis)
for the time between the first and last sample, and 0 prior to
the first sample.
Statistical Analysis
Socio-demographic, virological and clinical variables were
reported as absolute numbers, percentages and medians with
their respective interquartile ranges (IQR), where appropriate.
Their association with a Belgian F1 outbreak was evaluated using
univariate and multivariate logistic regression in the statistical R
software v3.5.1, with statistical significance set at p-value < 0.05.
For these analyses, only patients with available information for a
specific variable were included.
RESULTS
Increase of Subtype F1 Diagnoses in
Belgium
Up to February 2015, 297 HIV-1 sub-subtype F1 infections were
newly diagnosed in the participating Belgian ARL (Figure 1),
of which 137 were analyzed in Antwerp (46%), 95 in Brussels
(32%), 38 in Leuven (13%), and 27 in Ghent (9%). The median
age of people diagnosed with an HIV-1 sub-subtype F1 infection
was 34 years (IQR 29–41) and 77% were men. Over the course
of 15 years, the number of HIV-1 sub-subtype F1 diagnoses
increased from 3 in March 2001 – February 2003 to 88 in
March 2013 – February 2015 (Figure 1A). Sub-subtype F1
infections were initially mainly diagnosed in women (65%),
but after February 2005 men became the most affected gender
(87%). Of the sub-subtype F1 infections for which the respective
information was registered, the majority were diagnosed in
people born in Belgium (59%, 141/238) and in people who
declared that they probably acquired their infection in Belgium
(82%, 138/168). The sub-subtype F1 infections were found in
homosexual (51%, 117/231), heterosexual (35%, 80/231), and
bisexual risk (15%, 34/231) groups (Figure 1B).
The Belgian Sub-Subtype F1 Epidemic
Within a Global Context
Bayesian phylogenetic analyses were used to estimate the
geographical and temporal origin of the HIV-1 sub-subtype
F1 strains in our national cohort and to investigate viral
dissemination from Belgium to other countries. The final
dataset included 1866 sequences that were mainly sampled in
Europe (75%) and Brazil (20%) (Supplementary Table S1).
We found sufficient temporal signal to pursue phylodynamic
analysis and used the resulting empirical distribution of the dated
phylogenetic trees in a subsequently phylogeographic analysis.
The phylogeographic analysis revealed the divergence of sub-
subtype F1 into two well-supported clades for which (i) one
clade included mainly Brazilian and Portuguese strains together
with a Belgian subclade, while (ii) the other predominantly
Belgian, Romanian and Portuguese sequences (upper and lower
clade in Figure 2, Supplementary Figure S1). Their divergence
dates back 50 years ago (1968, 95% higher posterior density
(HPD) interval of 1963–1973), with an estimated start of local
dissemination of HIV-1 F1 in Brazil around 1973 (95% HPD
1969–1975) and subsequently in Portugal around 1979 (95%
HPD 1976–1981) (Figure 2 upper clade). In this upper clade
(i), one large Belgian cluster, subsequently referred to as the
sub-subtype F1 Belgian outbreak, is embedded within a Western-
European clade that in turn is nested within the larger Brazilian
clade. The Belgian clade contains four sequences sampled outside
Belgium (one from Brazil, one from Luxembourg, and two
from Germany), while the Western-European clade consists
of the Belgian clade together with three basal sequences from
Switzerland, one large well-supported Spanish clade and one
Romanian sequence that branches outside the Spanish and
Belgian clade. The founder of the HIV-1 sub-subtype F1 strains
that are currently circulating in Western-Europe, probably
migrated from Brazil to Europe between 1990 and 1999 (95%
HPD 1987–2002), whereas the origin of the Belgian and Spanish
outbreaks were dated back to 2002 (95% HPD 2000–2004) and
2006 (95% HPD 2004–2008), respectively. Brazil is estimated
as the most likely geographical origin of the Western-European
clade because the Western-European clade was embedded within
the large Brazilian sub-subtype F1 diversity and because one
strain that was sampled in Brazil and three strains that were
sampled from Brazilians residing in Belgium were also positioned
within the Belgian clade. Although Belgium was assigned as
ancestral location state of this Western-European clade, the
long interconnecting branch suggests that current sampling
is insufficient to provide conclusive results as to the specific
migration event(s) that finally led to the two large outbreaks in
Western Europe (Belgium and Spain).
The remaining sub-subtype F1 sequences from our Belgian
cohort represent single lineages or small clusters that are
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FIGURE 1 | HIV-1 sub-subtype F1 diagnoses in Belgium. Panel (A) Number of men and women diagnosed with an HIV-1 sub-subtype F1 infection according to
2-year intervals and based upon a pol-genotypic drug resistance test that was requested as part of routine clinical follow-up. The pie chart displays the proportion of
people who probably acquired the HIV-1 sub-subtype F1 infection in Belgium, Europe, Africa, or another or unknown region. Panel (B) Geographic and proportional
distribution of HIV-1 sub-subtype F1 diagnoses in the AIDS Reference Laboratories of Antwerp, Brussels, Leuven, and Ghent. The pie charts display the proportion
of people reporting homosexual, heterosexual, or bisexual contacts as risk factor for HIV-1 infection.
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FIGURE 2 | Phylogeographic reconstruction of the Belgian HIV-1 sub-subtype F1 epidemic. The branches in the time-scaled maximum clade credibility tree
constructed from the complete dataset of 1866 pol sequences are colored by their most probable location state (see legend), which could be a specific sampling
country or grouped as a continent when less than 30 sequences were available for a specific country (Supplementary Table S1). The HIV-1 sub-subtype F1 strains
that are associated with the local outbreak (191 lineages), most probably entered Belgium via Latin-America, more particularly Brazil, a transmission event that is
estimated to have occurred around 2002 (95% HPD 2000 – 2004). The 106 Belgian sequences that do not belong to the monophyletic group, are dispersed within
less recent clades, grouping with lineages from Africa, Latin-America and Europe. Posterior root node support is visualized in a selection of nodes.
dispersed across the tree and are intermixed among viral lineages
from Africa, Latin-America and Europe (Figures 2, 3). Several
other strains from Sub-Saharan migrants residing in Belgium but
who originated from the Democratic Republic of Congo (DRC),
Congo, and Angola occupied the most basal positions of the
tree (Figure 2 lower clade, Figure 3). They cluster with African
lineages that probably migrated to Europe between 1972 and 1977
(95% HPD 1969–1980) and that were at the origin of several
larger sub-subtype F1 outbreaks in Europe, more specifically
in Portugal (1979, 95% HPD 1976–1982), Romania (1981, 95%
HPD 1978–1983; 2001, 95% HPD 1996–2006; and 2002, 95%
HPD 1998–2006), and Bulgaria (1982, HPD 1979–1985). As, we
defined a location trait according to country of sampling in our
analysis, the over-representation of Belgian sequences – probably
to a large extent reflecting African diversity – led Belgium to be
inappropriately assigned as the ancestor location of this lower
clade that contained many African, Romanian, Portuguese, and
other European lineages (Figure 2 lower clade).
Socio-Epidemiological Correlates With
the Sub-Subtype F1 Outbreak in Belgium
As one or only a few sub-subtype F1 lineages have successfully
established local transmissions among 191 of 297 people
diagnosed with a sub-subtype F1 infection in Belgium (64%), we
used univariate and multivariate logistic regression to identify
socio-epidemiological variables that were associated with this
successful sub-subtype F1 outbreak in Belgium (Table 1). HIV-
1 patients who were diagnosed with a sub-subtype F1 infection
at the AIDS reference laboratories in Antwerp (OR 6.80, 95%
CI 3.86–11.99), Leuven (OR 4.22, 95% CI 1.59–11.16) or more
broadly in the region of Flanders (OR 7.28, 95% CI 4.23–12.53)
had significantly higher odds of belonging to this F1 outbreak,
compared to people who were diagnosed with a sub-subtype F1
infection elsewhere in Belgium. In addition, many other variables
of the sub-subtype F1 infections diagnosed in Belgium displayed
significantly higher odds of being part of the outbreak, of which
the most informative were male gender (OR 52.42, 95% CI
19.90–138.08), infection in MSM (combining homosexuals and
bisexuals) (OR 34.8, 95% CI 16.0–75.6), probable infection in
Belgium (OR 26.67, 95% CI 9.59–74.15), born in Belgium (OR
12.10, 95% CI 6.35-23.08), recent infection stage at diagnosis (OR
7.19, 95% CI 2.88–17.95) and higher viral load (OR 2.36, 95%
CI 1.78–3.13). In multivariate analysis, sub-subtype F1 infections
in MSM and in people born in Belgium remained to display a
higher likelihood for belonging to the sub-subtype F1 Belgian
outbreak [OR 7.82, 95% CI 3.80–16.11 and OR 2.01 (1.06–3.78),
respectively]. The variables sampling region, ARL in Belgium,
gender, country of birth and sexual risk group were visualized
for all Belgian sequences in a circular representation of the
phylogenetic tree (Figure 3).
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FIGURE 3 | Circular representation of the maximum clade credibility tree of the Belgian sub-subtype F1 epidemic within a global context. Branches in the tree are
colored according to sampling region (identical coloring scaling as in Figure 2), which is also displayed in layer 1. For the HIV-1 sub-subtype F1 strains that were
sampled at the AIDS reference laboratories (ARL) in Belgium, the location of testing was displayed in layer 2, gender in layer 3, country of birth in layer 4, and sexual
risk group in layer 5. This detailed information was largely lacking for the sequences sampled outside Belgium.
Reduced Onward Transmission of
Sub-Subtype F1 Strains Coincident With
an Earlier Initiation of Antiretroviral
Therapy
Since the onset of the sub-subtype F1 outbreak in Belgium
(2002, 95% HPD 2000–2004), we covered a time period where
antiretroviral therapy was initially still deferred in asymptomatic
patients with CD4 count above 350 cells/mm3 (European AIDS
Clinical Society, 2005). This general practice gradually switched
to the consideration of antiretroviral therapy for asymptomatic
patients with CD4 counts between 350 and 500 cells/mm3
(European AIDS Clinical Society, 2007) and above 500 cells/mm3
(European AIDS Clinical Society, 2013). Given the benefits
of antiretroviral therapy in reducing infectivity, we wanted to
quantify transmission dynamics through time using a birth-
death model and monitor the trends in therapy uptake in
our specific setting. Therapy and diagnosis information was
available for 147 HIV-1 patients whose viral strains belonged
to the sub-subtype F1 outbreak in Belgium (77%, 147/191).
The delay in therapy initiation decreased from a median of
1011 days (IQR 368–1683) or almost 3 years for patients
diagnosed in 2005 and 2006 to a median of 61 days (IQR 26–
208) or about 2 months for patients diagnosed in 2013 and
2014 (Figure 4). In the birth-death model, assuming a constant
65% sampling proportion, the number of expected secondary
infections per infected person (effective reproductive number
Re) was estimated to be a median of 3 in 2005 and gradually
declined to a median of 1.5 in 2011, after which a substantial drop
to below 1 was observed (Figure 5). During this time window,
the median infectious time also declined and the number of
expected secondary infections per infected person and per year
(transmission rate) decreased from a median of 1 to well below
1. Sensitivity analysis using a constant sampling proportion
of 80%, as the diagnosis and sequencing rate is expected to
be higher in MSM, showed similar results and suggests that
the estimates are relatively robust to prior specification on the
sampling proportion.
DISCUSSION
Human immunodeficiency virus type 1 subtype F most
likely emerged from the early 20th century HIV-1 diversity
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TABLE 1 | Characteristics of people diagnosed with an HIV-1 sub-subtype F1 infection in Belgium and factors associated with this local outbreak.
Characteristic Local outbreak
(n = 191)
Other (n = 106) Univariate logistic
regression
Multivariate logistic
regression
OR (95% CI) p OR (95% CI) p
AIDS Reference Laboratory [% (n)]
Antwerp 61.3 (117) 18.9 (20) 6.80 (3.86–11.99) < 0.0001
Brussels 16.7 (32) 59.4 (63) 0.14 (0.08–0.24) < 0.0001
Leuven 17.3 (33) 4.7 (5) 4.22 (1.59–11.16) 0.0037
Ghent 4.7 (9) 17.0 (18) 0.24 (0.10–0.56) 0.0009
Region [% (n)]
Flanders 83.3 (159) 40.6 (43) 7.28 (4.23–12.53) < 0.0001
Gender [% (n)]
Male 97.4 (186) 41.5 (44) 52.42 (19.90–138.08) < 0.0001
Age at diagnosis [years]
Median (IQR) 34 [29, 41] (190) 34 [27, 40] (92) 1.03 (1.00–1.06) 0.0343
Diagnosis date [dd-mm-yyyy]
Median [IQR] (n) 09-05-2012 24-1-2008 1.33 (1.23–1.45) < 0.0001
[21-03-2010,
23-11-2013] (190)
[3-4-2002,
31-10-2011] (92)
Infection stage at diagnosis [% (n)]
Acute 10.1 (16/158) 2.2 (1/45) 4.96 (0.64–38.45) 0.1256
Recent 52.5 (83/158) 13.3 (6/45) 7.19 (2.88–17.95) < 0.0001
Chronic 37.4 (59/158) 84.5 (38/45) 0.11 (0.05–0.26) < 0.0001
Unknown 17.2 (33) 57.5 (61)
Country of birth [% (n)]
Belgium 77.8 (123/158) 22.5 (18/80) 12.10 (6.35–23.08) < 0.0001 2.01 (1.06– 0.0316
Other 22.2 (35/158) 77.5 (62/80) 3.78)
Unknown 17.2 (33) 24.5 (26)
Probable country of infection [% (n)]
Belgium 95.2 (120/126) 42.9 (18/42) 26.67 (9.59–74.15) < 0.0001
Other 4.8 (6/126) 57.1 (24/42)
Unknown 34.0 (65) 60.4 (64)
Sexual risk group [% (n)]
Homosexual contacts 69.2 (110/159) 9.7 (7/72) 20.85 (8.92–48.73) < 0.0001 < 0.0001
Bisexual contacts 18.2 (29/159) 7.0 (5/72) 2.99 (1.11–8.08)
Heterosexual contacts 12.6 (20/159) 83.3 (60/72) 0.03 (0.01–0.06) 0.0308
Men-having-sex-with-men 87.4 (139/159) 16.7 (12/72) 34.8 (16.0–75.6) < 0.0001 7.82 (3.80–
Unknown 16.8 (32) 32.1 (34) < 0.0001 16.11)
Viral load at sequencing [log10
copies/ml] Median [IQR] (n) 5.18 [4.61–5.79] (191) 4.36 [3.75, 4.92] (101) 2.36 (1.78–3.13) < 0.0001
CD4+ at sequencing [cells/µl]
Median [IQR] (n) 488 [358–645] (184) 334 [175, 528] (89) 1.00 (1.00–1.00) < 0.0001
CD8+ at sequencing [cells/µl]
Median [IQR] (n) 1059 [697–1598] (173) 1041 [778, 1390] (67) 1.00 (1.00–1.00) 0.2980
A univariate and multivariate logistic regression analysis was performed to identify socio-epidemiological variables that were associated with the local HIV-1 F1 outbreak
in Belgium (n = 191). A p-value of < 0.05 was considered to be significant. Abbreviations: n, number, IQR, interquartile range, OR, odds ratio, CI, confidence interval.
in the DRC, where its current prevalence remains less
than 5% (Vidal et al., 2000; Faria et al., 2014; Rodgers
et al., 2017). This subtype accounts for less than 1%
of HIV-1 infections worldwide and is subdivided into
two sub-subtypes F1 and F2, of which the detection
of the latter remains mostly restricted to Cameroon
(Brennan et al., 2008; Hemelaar et al., 2011). In contrast,
sub-subtype F1 strains have spread to other Central
African countries, reaching a particularly high prevalence
of 14% in Angola (Afonso et al., 2012). In Belgium,
the burden of sub-subtype F1 infections among newly
diagnosed HIV-1 patients increased to 11.1% in 2015.
The aim of this study was to characterize the epidemic
dynamics of this non-B subtype epidemic in Belgium
by using phylogenetic approaches and the analysis of
socio-epidemiological variables.
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FIGURE 4 | Delay in antiretroviral treatment among people infected with
sub-subtype F1 strains belonging to the local outbreak in Belgium. The
number of days between diagnosis date and treatment initiation date were
plotted according to 2-year intervals of diagnosis date. Information on
prescribed antiviral therapy and diagnosis date was available for 77% of the
HIV-1 patients belonging to the local outbreak in Belgium (147/191).
The Dissemination of HIV-1 Sub-Subtype
F1 Across the World
Our and other phylogenetic analyses confirmed that the most
basal F1 sequences were isolated from people originating from
Central African countries and that the major migration events
out of Africa occurred in the 1970s and early 1980s seeding some
larger F1 epidemics over the world (Mehta et al., 2011; Bello et al.,
2012; Lai et al., 2014). During the Angolan civil war that started in
1975 and lasted for more than 16 years, an extensive migration of
troops, settlers and refugees was observed between Angola, DRC,
Portugal, Brazil, Cuba, Russia, and several Eastern-European
countries and this is considered as an important factor in the
global dissemination of F1. In Brazil, sub-subtype F1 infections
have reached prevalence rates of more than 7% and the strains
are currently circulating among various risk groups (Brindeiro
et al., 2003). It is the most probable epicenter of F1-related
epidemics within the Southern Cone and one of the sources of the
Portuguese sub-subtype F1 epidemic (Aulicino et al., 2007; Bello
et al., 2007, 2012; Carvalho et al., 2015). Unrelated to the Brazilian
epidemic, sub-subtype F1 was initially introduced and spread
among adult heterosexuals in Romania. In this Eastern-European
country, it subsequently reached a very high prevalence rate of
more than 70% due to several major outbreaks among children
in orphanages and people using intravenous drugs (Dumitrescu
et al., 1994; Bandea et al., 1995; Apetrei et al., 1998; Op De Coul
et al., 2000; Guimarães et al., 2009; Paraschiv et al., 2009; Mehta
et al., 2011; Mbisa et al., 2012; Niculescu et al., 2014). Both Brazil
and Romania were at the origin of the F1 epidemic in Italy, where
Brazilian strains contributed to many more introduction events
characterized with a more extensive spread (Lai et al., 2014).
Since then, the prevalence of sub-subtype F1 increased gradually
among Italian descendants and mainly among self-declared
heterosexual men, although phylogenetic analyses suggested that
some of these self-declared heterosexual men might have been
infected through homosexual contact (Bracciale et al., 2009;
Lai et al., 2012, 2014).
Although our and a previous study indicated that another
sub-subtype F1 lineage migrated from Brazil to Europe during
the 1990s, this lineage obtained only more recently epidemic
proportions in two countries, respectively, about 16 years ago
in Belgium and 12 years ago in Spain (Paraskevis et al., 2015).
In both instances, F1 was introduced in local MSM networks,
a factor probably important in its subsequent spread and
circulation at high rates (Thomson et al., 2012). Our analyses
did not indicate any intermixing between both epidemics and
only sporadic and putative exports from Belgium to Luxembourg
(one) and Germany (two) were detected. This is in agreement
with another study that traced the HIV-1 subtype B mobility
in Europe and that characterized Belgium primarily as a sink
of HIV-1 lineages rather than a source (Paraskevis et al., 2009).
Although, we confirmed previous findings on the global spread
of HIV-1 sub-subtype F1, our sampling approach might not have
been sensitive enough to capture the specific migration events
that resulted into these two large outbreaks or into extensive
onward transmission to other countries. For our analyses, we
collected HIV-1 pol sequences from countries with a known
high burden of F1 infections or a potential role in the global
spread of sub-subtype F1. In this dataset, Belgium, Romania,
Portugal, Luxembourg, and Bulgaria were the best-represented
countries as they contributed a dense sampling, whereas Italy
provided a down-sampling proportional to their local sub-
subtype F1 diversity. However, other countries might have been
undersampled as they were represented by sequences that were
received from single cohorts or by sequences that were collected
from public databases. Such sample biases call for caution in
interpreting the results of phylogeographic estimates.
The Belgian HIV-1 Sub-Subtype F1
Outbreak
The first HIV-1 sub-subtype F1 infections within the local
outbreak cluster were diagnosed in 2005. It concerned one
chronic infection in Leuven and one infection with unknown
status in Antwerp, suggesting a time of about 3 years between
the estimated introduction in Belgium (2002, 95% HPD 2000–
2004) and the first case reported by the Belgian ARL. Although
there is universal access to HIV-1 health care in Belgium and we
included all patients for whom genotypic drug resistance testing
indicated a sub-subtype F1 infection, whether at baseline or at
therapeutic failure, our sequencing efforts in routine practice
only cover approximately 60% of all newly HIV-1 diagnoses
registered in the national database. However, we believe that
we do capture the majority of patients who are contributing
to the local spread, as sub-subtype F1 is mainly circulating
among MSM, a group who is well engaged in medical care
(Van Beckhoven et al., 2015). Any HIV-1 patient who seeks
medical care in Belgium will receive a confirmation of his/her
infection and will therefore be registered in the national database.
Therefore, we believe that a large proportion of the people living
with HIV-1 in Belgium who do not receive a baseline resistance
test at diagnosis are people with an infection that was already
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FIGURE 5 | Birth-death model applied to the sub-subtype F1 outbreak in Belgium. For all patients belonging to the large Belgian cluster (n = 191), the number of
secondary infections per infected person (effective reproductive number Re, panel (A)), the median infectious time in years (panel (B)) and the number of secondary
infections per infected person per year (transmission rate, panel (C)) was estimated. After the onset of the outbreak both Re and transmission rate started to decline,
with the largest drop occurring after 2011.
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acquired and diagnosed abroad and who are already on successful
antiretroviral treatment upon arrival in Belgium, or these people
are only temporarily in the country and do not enter the HIV-1
health care system in Belgium.
With the dense sampling of our local epidemic at hand, we
aimed to estimate the effective reproductive number Re, the
transmission (birth) rates and the time of being infectious in
our viral population using birth-death modeling in order to
gain insights into the dynamics of the outbreak. The initial
high Re-value, high transmission rate and long times of being
infectious were in agreement with the explosive increase of
sub-subtype F1 infections in our national cohort. However,
the mean Re-value declined substantially from 2012 onward
and this event was associated with lower transmission rates
and shorter durations of being infectious. These observations
may be explained by the policy changes around that time
when therapy eligibility thresholds for asymptomatic HIV-1
patients became less strict in Belgium. Indeed, medical records
showed a remarkable dent in the median treatment delay
among people belonging to our outbreak around 2009–
2010. Although this relationship does not demonstrate
causality, it is supported by studies where viral suppression
by antiretroviral therapy has shown to be effective in preventing
HIV-1 transmission among serodiscordant heterosexual
and MSM couples (Cohen et al., 2011; Rodger et al., 2016;
Bavinton et al., 2018). However, the relevant changes in
transmission dynamics were not yet reflected in the number
of new sub-subtype F1 diagnoses up to the start of 2015.
This could suggest that the effects were too recent to be
fully captured by our surveillance data of new diagnoses or
that the conditions were not yet fully optimal to achieve the
full potential of treatment as prevention in this outbreak
(Okano et al., 2016). Although a substantial proportion of
our outbreak was diagnosed at an acute and recent stage of
infection, we should aim to increase testing and diagnosis
rates among people at risk of acquiring HIV-1 and treat
them without any delay. In this respect, the INSIGHT START
study resolved the last concerns for immediate initiation of
antiretroviral therapy in asymptomatic HIV-1 infections as
this study showed that this strategy was superior to deferral
until the CD4 count declined to 350 cells/mm3 and that it
was not associated with an increased rate of adverse events
(INSIGHT START Study Group et al., 2015).
In conclusion, this study revealed that sub-subtype F1 strains
were introduced in Belgium around 2002 and that during
a decade they spread exponentially among MSM who were
mainly from Belgian descent, residing in Flanders and diagnosed
at a recent stage of infection. Our birth-death phylodynamic
estimates are in line with the expectations of the effectiveness
of treatment as prevention because we identify a decline in the
onward transmission of sub-subtype F1 strains that coincides
with the implementation of earlier initiation of antiretroviral
therapy in our cohort. Further follow-up is planned, especially
within the context of the roll-out of antiretroviral therapy in early
asymptomatic HIV-1 infections and of the implementation of
pre-exposure prophylaxis which is reimbursed to people who are
at increased risk for HIV-1 infection since June 2017.
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